Overview
Efficacy, Safety and Tolerability of Rotigotine Nasal Spray for the Acute Treatment of RLS Symptoms
Status:
Completed
Completed
Trial end date:
2006-12-01
2006-12-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
The main objective of this phase 2a proof-of-concept trial is to assess the efficacy of rotigotine nasal spray in ascending doses in subjects with idiopathic Restless Legs Syndrome.Phase:
Phase 2Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
UCB PharmaTreatments:
N 0437
Rotigotine
Criteria
Inclusion Criteria:- Subjects with idiopathic RLS, who are responding to an ongoing L-dopa treatment
Exclusion Criteria:
- Patients with secondary RLS or clinically relevant concomitant diseases or medical
conditions are excluded